Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2006 1
2013 1
2014 2
2015 2
2017 2
2020 1
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial.
Khanani AM, Patel SS, Staurenghi G, Tadayoni R, Danzig CJ, Eichenbaum DA, Hsu J, Wykoff CC, Heier JS, Lally DR, Monés J, Nielsen JS, Sheth VS, Kaiser PK, Clark J, Zhu L, Patel H, Tang J, Desai D, Jaffe GJ; GATHER2 trial investigators. Khanani AM, et al. Lancet. 2023 Oct 21;402(10411):1449-1458. doi: 10.1016/S0140-6736(23)01583-0. Epub 2023 Sep 8. Lancet. 2023. PMID: 37696275
Efficacy and Safety of the Aflibercept Biosimilar SB15 in Neovascular Age-Related Macular Degeneration: A Phase 3 Randomized Clinical Trial.
Woo SJ, Bradvica M, Vajas A, Sagong M, Ernest J, Studnicka J, Veith M, Wylegala E, Patel S, Yun C, Orski M, Astakhov S, Tóth-Molnár E, Csutak A, Enyedi L, Kim T, Oh I, Jang H, Sadda SR. Woo SJ, et al. Among authors: bradvica m. JAMA Ophthalmol. 2023 Jul 1;141(7):668-676. doi: 10.1001/jamaophthalmol.2023.2260. JAMA Ophthalmol. 2023. PMID: 37289448 Free PMC article. Clinical Trial.
Biosimilar SB15 versus reference aflibercept in neovascular age-related macular degeneration: 1-year and switching results of a phase 3 clinical trial.
Woo SJ, Sadda SR, Bradvica M, Vajas A, Sagong M, Ernest J, Studnička J, Veith M, Wylegala E, Patel S, Yun C, Orski M, Astakhov S, Tóth-Molnár E, Csutak A, Enyedi L, Choi W, Oh I, Jang H. Woo SJ, et al. Among authors: bradvica m. BMJ Open Ophthalmol. 2023 Dec 19;8(1):e001561. doi: 10.1136/bmjophth-2023-001561. BMJ Open Ophthalmol. 2023. PMID: 38114333 Free PMC article. Clinical Trial.
Biosimilars of anti-vascular endothelial growth factor for ophthalmic diseases: A review.
Bressler NM, Kaiser PK, Do DV, Nguyen QD, Park KH, Woo SJ, Sagong M, Bradvica M, Kim MY, Kim S, Sadda SR. Bressler NM, et al. Among authors: bradvica m. Surv Ophthalmol. 2024 Mar 21:S0039-6257(24)00029-8. doi: 10.1016/j.survophthal.2024.03.009. Online ahead of print. Surv Ophthalmol. 2024. PMID: 38521423 Free article. Review.
Diagnostic and therapeutic challenges.
Vinkovic M, De Salvo G, Biuk D, Bradvica M, Matic S, Walsh MK. Vinkovic M, et al. Among authors: bradvica m. Retina. 2014 Dec;34(12):2487-9. doi: 10.1097/IAE.0000000000000102. Retina. 2014. PMID: 24521709 No abstract available.
13 results